{"id":"cc-5013-revlimid","safety":{"commonSideEffects":[{"rate":"50-60","effect":"Neutropenia"},{"rate":"40-50","effect":"Thrombocytopenia"},{"rate":"30-40","effect":"Anemia"},{"rate":"30-40","effect":"Fatigue"},{"rate":"20-30","effect":"Constipation"},{"rate":"15-25","effect":"Diarrhea"},{"rate":"10-20","effect":"Neuropathy"},{"rate":"10-15","effect":"Thromboembolism"}]},"_chembl":{"chemblId":"CHEMBL3916385","moleculeType":"Small molecule","molecularWeight":"502.67"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Lenalidomide binds to cereblon (CRBN), a component of an E3 ubiquitin ligase complex, leading to selective degradation of Ikaros and Aiolos proteins. This results in enhanced IL-2 and IFN-γ production by T cells, increased NK cell activity, and inhibition of pro-inflammatory cytokines. Additionally, it has direct cytotoxic effects on certain malignant cells and inhibits angiogenesis.","oneSentence":"CC-5013 (lenalidomide) is an immunomodulatory agent that enhances T-cell proliferation and NK cell activation while inhibiting TNF-α and IL-6 production, and also has direct anti-angiogenic and anti-proliferative effects on tumor cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:05:01.786Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Multiple myeloma"},{"name":"Myelodysplastic syndromes with deletion 5q"},{"name":"Mantle cell lymphoma"}]},"trialDetails":[{"nctId":"NCT05683171","phase":"PHASE1, PHASE2","title":"A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2023-05-19","conditions":"Lymphoma","enrollment":60},{"nctId":"NCT05730036","phase":"PHASE3","title":"A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2023-09-18","conditions":"Relapsed Refractory Multiple Myeloma (RRMM)","enrollment":410},{"nctId":"NCT05091372","phase":"PHASE2","title":"Minimal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lenalidomide After Autologous Hematopoietic Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2022-12-01","conditions":"Myeloma Multiple","enrollment":94},{"nctId":"NCT04623541","phase":"PHASE1, PHASE2","title":"Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genmab","startDate":"2020-11-25","conditions":"Relapsed/Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Richter's Syndrome","enrollment":195},{"nctId":"NCT04663347","phase":"PHASE1, PHASE2","title":"Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genmab","startDate":"2020-11-03","conditions":"Diffuse Large B-Cell Lymphoma, Follicular Lymphoma","enrollment":543},{"nctId":"NCT06191744","phase":"PHASE3","title":"Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma","status":"RECRUITING","sponsor":"Genmab","startDate":"2024-02-05","conditions":"Follicular Lymphoma (FL)","enrollment":1095},{"nctId":"NCT05660967","phase":"PHASE2","title":"Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genmab","startDate":"2023-03-06","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":111},{"nctId":"NCT04542824","phase":"PHASE1, PHASE2","title":"Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genmab","startDate":"2020-08-20","conditions":"Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Primary Mediastinal Large B Cell Lymphoma","enrollment":78},{"nctId":"NCT07428369","phase":"PHASE2, PHASE3","title":"A Study of Linvo-VR vs DVRd in Transplant-Eligible Adult Participants With Newly Diagnosed Multiple Myeloma (NDMM)","status":"NOT_YET_RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2026-06-05","conditions":"Multiple Myeloma (MM)","enrollment":1570},{"nctId":"NCT06207799","phase":"PHASE2","title":"Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-07-17","conditions":"Multiple Myeloma, Post-transplant MRD-guided Maintenance Therapy, Pre-transplant Purging","enrollment":40},{"nctId":"NCT05137054","phase":"PHASE1","title":"A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2022-08-17","conditions":"Multiple Myeloma","enrollment":317},{"nctId":"NCT07285239","phase":"PHASE3","title":"Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma","status":"NOT_YET_RECRUITING","sponsor":"PrECOG, LLC.","startDate":"2026-05","conditions":"Multiple Myeloma","enrollment":500},{"nctId":"NCT02728102","phase":"PHASE2","title":"Dendritic Cell/Myeloma Fusion Vaccine for Multiple Myeloma (BMT CTN 1401)","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2016-07","conditions":"Multiple Myeloma","enrollment":203},{"nctId":"NCT00305812","phase":"PHASE2","title":"Lenalidomide and Melphalan in Treating Patients With Previously Untreated Multiple Myeloma","status":"COMPLETED","sponsor":"NCIC Clinical Trials Group","startDate":"2006-03-09","conditions":"Multiple Myeloma and Plasma Cell Neoplasm","enrollment":51},{"nctId":"NCT03003520","phase":"PHASE2","title":"A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma","status":"COMPLETED","sponsor":"Celgene","startDate":"2017-02-28","conditions":"Lymphoma, Large B-Cell, Diffuse","enrollment":46},{"nctId":"NCT03411031","phase":"PHASE2","title":"Elotuzumab Plus Lenalidomide (Elo/Rev) for Serologic Relapse/Progression While on Lenalidomide","status":"TERMINATED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2018-10-04","conditions":"Multiple Myeloma","enrollment":18},{"nctId":"NCT01109004","phase":"PHASE3","title":"Stem Cell Transplant With Lenalidomide Maintenance in Patients With Multiple Myeloma (BMT CTN 0702)","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2010-05","conditions":"Multiple Myeloma","enrollment":758},{"nctId":"NCT02128230","phase":"PHASE2","title":"UARK 2012-02 Trial For High-Risk Myeloma Evaluating Accelerating and Sustaining Complete Remission","status":"TERMINATED","sponsor":"University of Arkansas","startDate":"2014-06-10","conditions":"Multiple Myeloma","enrollment":20},{"nctId":"NCT02322320","phase":"PHASE3","title":"Continued, Long-Term Follow-Up and Lenalidomide Maintenance Therapy for Patients on BMT CTN 0702 Protocol (BMT CTN 07LT)","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2015-03","conditions":"Multiple Myeloma","enrollment":273},{"nctId":"NCT00294632","phase":"PHASE1, PHASE2","title":"Lenalidomide and Rituximab in the Treatment of Relapsed Mantle Cell Lymphoma (MCL) and Diffuse Large B-Cell Lymphoma","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2006-02","conditions":"Lymphoma","enrollment":54},{"nctId":"NCT00553644","phase":"PHASE2","title":"Bortezomib and Lenalidomide in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2007-11-15","conditions":"Recurrent Mantle Cell Lymphoma","enrollment":53},{"nctId":"NCT01133743","phase":"PHASE2","title":"Open-Label Study of Lenalidomide in Combination With Oral Dexamethasone in the Treatment of Previously Untreated, Symptomatic Patients With Chronic Lymphocytic Leukemia","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2010-05","conditions":"Chronic Lymphocytic Leukemia","enrollment":31},{"nctId":"NCT00482911","phase":"PHASE2","title":"Lenalidomide, Sunitinib, and Cyclophosphamide in Treating Patients With Stage IV Eye Melanoma","status":"TERMINATED","sponsor":"National Institutes of Health Clinical Center (CC)","startDate":"2007-04","conditions":"Intraocular Melanoma, Malignant Conjunctival Neoplasm","enrollment":12},{"nctId":"NCT00238238","phase":"PHASE2","title":"Rituximab and/or Lenalidomide in Treating Patients With Follicular Non-Hodgkin's Lymphoma That is Not Refractory to Rituximab","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2006-03","conditions":"Lymphoma","enrollment":97},{"nctId":"NCT00495872","phase":"PHASE1","title":"Valproic Acid-Based 2-Agent Oral Regimens for Patients With Advanced Solid Tumor","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2007-06","conditions":"Solid Tumors","enrollment":204},{"nctId":"NCT00093028","phase":"PHASE3","title":"Study of Bortezomib and Revlimid™ for Patients Relapsing or Progressing on Total Therapy II","status":"COMPLETED","sponsor":"University of Arkansas","startDate":"2004-01","conditions":"Multiple Myeloma","enrollment":315},{"nctId":"NCT00253344","phase":"PHASE1","title":"Lenalidomide and Docetaxel in Treating Patients With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Case Comprehensive Cancer Center","startDate":"2005-06","conditions":"Unspecified Adult Solid Tumor, Protocol Specific","enrollment":33}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":139,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"CC-5013 (Revlimid™)","genericName":"CC-5013 (Revlimid™)","companyName":"University of Arkansas","companyId":"university-of-arkansas","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CC-5013 (Revlimid) is a small molecule used in the treatment of multiple myeloma and plasma cell neoplasm, as well as other conditions such as intraocular melanoma and lymphoma. It has been studied in combination with other medications, including cyclophosphamide and sunitinib malate, in clinical trials.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}